• This 5-Star Analyst Is Bullish on AMD’s Strong Roadmap

    This 5-Star Analyst Is Bullish on AMD’s Strong RoadmapThe last five years have been one unstoppable ride to the summit for chipmaker Advanced Micro Devices (AMD). Simultaneously closing the gap between its traditionally bigger rivals, Intel and Nvidia, and itself, the CPU/GPU maker is now most definitely a force to be reckoned with.Following an investor call with the company, Nomura analyst David Wong sees no reason to change tack when considering AMD as an investment.The 5-star analyst has a Buy rating on AMD shares to go along with a $64 price target. The implication for investors? Potential upside of 18% from current levels. (To watch Wong’s track record, click here)Behind AMD’s growth has been an exemplary roadmap. Still to come in 2020 is the launch of the highly anticipated Milan data center CPU, the third generation EPYC processor. Add to that the release of a new data center GPU “optimized on CDMA data center optimized architecture,” a new consumer GPU (Big Navi on RDNA 2), and Zen 3 desktop CPUs.AMD has stated its “product cadence” has been “condensed” so that new generations could hit the market every five or six quarters. Desktops and servers are usually first in line, followed by notebooks.“Given that AMD intends to launch a new generation of desktop and server CPUs near the end of 2020 and recently launched a new generation of notebook processors, this cadence implies that there may be a new generation of notebook processors in 2021 and a new generation of desktop and server processors in late 2021, or more likely the first part of 2022,” Wong said.The company’s aim of achieving between 20% to 30% year-over-year revenue growth in 2020 appears to be on track, too. In addition, despite the fact that this quarter’s ramp up of new semi-custom products for next-generation game consoles has had a “temporary impact” on gross margins, the chipmaker’s long-term goal of bringing in gross margins of over 50% hasn’t changed, either.Now let’s take a look at what the rest of the Street currently makes of AMD; Based on 12 Buys and 8 Holds, AMD has a Moderate Buy consensus rating. The analysts forecast a modest upside of 2%, should the $56.56 average price target be met over the next 12 months. (See AMD stock analysis on TipRanks)To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Fulgent Pops 18% In After-Market On FDA Nod For Covid-19 Home Test * Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined * Groupon Rises After-Hours Despite Revenue Plunging 35% Y/Y * Google and Carrefour Roll Out Voice-Based Shopping Service In France

    from Yahoo Finance https://ift.tt/2C5XkgX

  • 3 ASX growth shares to buy with $3,000

    growth shares

    If you have room in your portfolio for a few growth shares, then I think the three listed below could be top options.

    I believe all three are well-positioned to deliver above-average earnings growth over the next few years and could generate strong returns for investors. Here’s why I’m positive on them and would invest $3,000 across their shares:

    Bubs Australia Ltd (ASX: BUB)

    The first growth share to look at is Bubs. It is a goat’s milk-focused infant formula and baby food company. Whilst I’ve been a fan of Bubs for a while, it is only really now that I think it is investment grade. This is because for a long time its strong sales growth was coming with significant losses. This led to the company burning through cash at a rapid rate. However, Bubs recently reported positive operating cashflow of $2.3 million on record quarterly revenue of $19.7 million. I’m optimistic the company has now reached a scale which will make its operations more and more profitable over the coming years. As a result, I think it could be a good long term option for investors.

    Pro Medicus Limited (ASX: PME)

    Another growth share that I think has a lot of potential is Pro Medicus. This healthcare technology company provides radiology IT software and services to hospitals, imaging centres, and healthcare groups. The product in its portfolio that I’m most excited about is the popular Visage 7 Enterprise Imaging Platform. It delivers fast, multi-dimensional images which are streamed via an intelligent thin-client viewer. Demand for Visage 7 has been strong and the company recently announced a major new contract with one of the highest rated hospitals in the United States. In addition to this, it revealed that it has a number of sales opportunities in its pipeline that it is working on. I believe this bodes well for its future growth.

    Xero Limited (ASX: XRO)

    A final ASX growth share I think investors ought to consider buying is Xero. I think the provider of cloud-based business and accounting software is arguably one of best growth shares on offer on the ASX. This is due to the increasing demand for its platform from small businesses and the stickiness of its product. Combined, they are resulting in significant recurring revenues which I feel are only likely to grow larger in the coming years as more and more businesses move over to the cloud.

    And here are more exciting shares which could be stars of the future…

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of BUBS AUST FPO and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended BUBS AUST FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 ASX growth shares to buy with $3,000 appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3fqC8Rc

  • AUD/USD Price Forecast – Australian Dollar Continues Choppy Behavior

    AUD/USD Price Forecast – Australian Dollar Continues Choppy BehaviorThe Australian dollar initially tried to rally during the trading session on Tuesday but gave back the gains as soon as we get close to the 0.70 level.

    from Yahoo Finance https://ift.tt/37zPRCu

  • Should You Avoid Momo Inc (MOMO)?

    Should You Avoid Momo Inc (MOMO)?The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

    from Yahoo Finance https://ift.tt/37tJgJY

  • Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined

    Amarin, Apotex Settle Vascepa Dispute; Analyst Stays SidelinedAmarin (AMRN) has announced a settlement agreement with Apotex Inc. that resolves a patent litigation over Apotex’s abbreviated new drug application (ANDA) seeking US approval of a generic form of Vascepa capsules. Shares in Amarin rose 5% in Tuesday’s after-market trading.Amarin’s lead product Vascepa was initially launched in the US in 2013 as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. A new, cardiovascular risk indication for the fish-oil derivative was approved by the FDA in December 2019 based on the results of the landmark Reduce-It trial.The company is currently appealing to the U.S. Court of Appeals a March 2020 patent invalidity ruling in favor of generic companies, Hikma Pharmaceuticals USA Inc. and Dr. Reddy’s Laboratories, Inc. Because Apotex is not a party to that litigation, it is not directly subject to related rulings.As part of the new settlement agreement, Apotex can not sell a generic Vascepa in the US until August 9, 2029 (the same date as Amarin’s 2018 settlement agreement with Teva (TEVA)) or earlier under certain customary circumstances.  These circumstances include if Amarin is not successful in its pending appeal of the March 2020 Nevada district court decision.The agreement also substantially resolves future litigation with Apotex that relating to the December 2019 cardiovascular risk reduction indication of Vascepa, says Amarin.“This settlement involves no financial payment from Amarin to Apotex and allows Amarin to avoid incremental litigation expense and distraction associated with Apotex’s participation in patent litigation related to the MARINE and REDUCE-IT indications,” said John F. Thero, Amarin CEO.Year-to-date shares in Amarin have plunged 68%, but analysts retain a cautiously optimistic Moderate Buy outlook on the stock. This breaks down into 7 recent buy ratings vs 5 hold ratings. Meanwhile the average analyst price target of $18 translates into 155% upside potential. (See Amarin stock analysis on TipRanks)Stifel Nicolaus analyst Derek Archila reiterated his Amarin Hold rating following the settlement announcement. “While this is a slight positive, we don’t see this a major stock moving catalyst” he wrote, adding that he expects AMRN shares to remain range bound until it gets closer to the critical appeal hearing later this year.Related News: Too Much Uncertainty Keeps This 5-Star Analyst Watching Amarin Stock From the Sidelines Jazz Pharma Scores Surprise Early Approval For Lung Cancer Treatment Merck’s Gardasil Receives FDA Nod For Expanded Cancer Indications More recent articles from Smarter Analyst: * Fulgent Pops 18% In After-Market On FDA Nod For Covid-19 Home Test * Groupon Rises After-Hours Despite Revenue Plunging 35% Y/Y * Google and Carrefour Roll Out Voice-Based Shopping Service In France * Facebook Unveils Tighter Political Ad Measures Ahead of US Elections

    from Yahoo Finance https://ift.tt/3ebRAAt

  • Fund managers have been buying these ASX shares

    ASX buy

    I like to keep an eye on substantial shareholder notices. This is because these notices give you an idea of which shares large investors, asset managers, and investment funds are buying or selling.

    Two notices that have caught my eye today are summarised below. Here’s what these fund managers have been buying:

    Computershare Limited (ASX: CPU)

    A notice of change of interests of substantial holder shows that AustralianSuper has taken advantage of Computershare’s share price weakness to increase its stake. According to the notice, the super fund has picked up approximately 8 million of this share registry company’s shares over the last four months. This has lifted its holding to a total of ~41.1 million shares, which represents a 7.59% stake in the company.

    The Computershare share price is down 27% from its 52-week high. Judging by its purchases, this has left its shares trading at a level that AustralianSuper thinks is attractive. One broker that would agree with this is Morgans. Last month the broker put an add rating and $13.90 price target on the company’s shares.

    Medibank Private Ltd (ASX: MPL)

    A notice of initial substantial holder reveals that Perpetual Limited (ASX: PPT) has been building a position in this private health insurer over the last few months. Perpetual started buying in February when Medibank’s shares were trading at $3.06. It then continued to purchase shares in March when they fell to ~$2.60 and has consistently added to its holding since then. Its last recorded purchase came on 11 June for $3.01. In total Perpetual now owns 140,759,820 shares, which represents a 5.11% stake in the company.

    As with AustralianSuper and Computershare, it appears as though the fund manager sees value in Medibank’s shares after they fell 18% from their high. Affordability issues have been weighing heavily on the company over the last 12 months, but AustralianSuper doesn’t appear concerned.

    And here are more quality shares which I think fund managers could be buying…

    5 ASX stocks under $5

    One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.

    Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Fund managers have been buying these ASX shares appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3dbzttb

  • 5 ASX shares that would’ve made you a fortune in 5 years

    Wealthy man with money raining down, cheap stocks

    Finding ASX shares that can make you a fortune in just 5 years is every investor’s dream. Investing in that one knockout winner can make a life-changing impact on your portfolio and your personal wealth. Of course, the ASX boards are littered with the broken dreams of those investors who’ve made the wrong bets. We can’t all find the next Amazon.com.

    But we can take a look at some past ASX winners that made their investors very rich over the past 5 years.

    CSL Limited (ASX: CSL)

    CSL is one of those rare shares that has made an absolute motza for its investors over the past 5 years, despite its size and blue chip status. Five years ago, CSL shares were trading at $87.40 each. Fast forward to today and CSL shares will set you back $286.22 (at the time of writing). That’s a 227% gain in 5 years.

    Xero Limited (ASX: XRO)

    Xero has been another ASX fortune maker over the past 5 years. This cloud-based accounting software provider was a slow burner in its infancy but has really stepped on the gas over the past few years, as its scalable business model works its magic. Five years ago, Xero shares were asking just $17.06. Today, those same shares will set you back $88.39. That’s more than 400% in gains that investors have enjoyed since 2015.

    Northern Star Resources Ltd (ASX: NST)

    It’s not often that ASX gold miners are cited as favoured money makers, but ask any Northern Star shareholder for their opinion on the matter. This mid-cap miner’s shares have spent the past 5 years rocketing from $2.28 in 2015 to $13.20 today. If you go back another 5 years to 2010, Northern Star was just 6 cents per share. Who said that gold doesn’t glitter! Any lucky shareholder that acquired Northern Star ownership in 2015 would be looking at nearly a 480% gain today. And for anyone who got in back in 2010? Hello 22,000%.

    Afterpay Ltd (ASX: APT)

    Afterpay’s phenomenal success would probably be familiar to every ASX investor by now. After all, this buy now, pay later pioneer is a share that is up more than 35% in just the last month alone. But what of those long-term investors in Afterpay? Well, back in 2015, you could have picked up Afterpay shares for just $2.95. Fast forward to today and Afterpay is making yet more record highs, going for $57.34 at the time of writing. That’s a 1,844% return since 2015. Talk about a fortune maker!

    Fortescue Metals Group Limited (ASX: FMG)

    Much like CSL, this ASX blue chip iron miner doesn’t immediately come to mind as a ‘multi-bagger‘ share. Yet this company’s numbers tell a different story. Back in 2015, you could have picked up some Fortescue shares for just $2.16. Today, those same shares will set you back $14.61 – netting any lucky buyer in 2015 a 576% increase in their fortune. Not bad for a red dirt digger.

    For some potential multi-baggers of tomorrow, make sure you check out the shares named below.

    3 “Double Down” stocks to ride the bull market higher

    Motley Fool resident tech stock expert Dr. Anirban Mahanti has identified three stocks he thinks can ride the bull market even higher, potentially supercharging your wealth in 2020 and beyond.

    Doc Mahanti likes them so much he has issued “double down” buy alerts on all three stocks to members of his Motley Fool Extreme Opportunities stock picking service.

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Xero. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 ASX shares that would’ve made you a fortune in 5 years appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/37FWljh

  • Why I think Bellevue shares are ‘gold’ for your portfolio

    Hand holding solid gold bar in front of neutral background

    Warren Buffett’s famous No.1 rule is “never lose money”. Clearly this is sage advice, however, I have always tempered this rule with “focus on things that will make you money”. I think Bellevue Gold Ltd (ASX: BGL) shares are one of the ASX companies likely to make you money.

    And I’m happy to have a small stake in the company. 

    I think Bellevue shares are a great growth opportunity in the gold mining sector as well as one of the best opportunities in mining shares.

    Why Bellevue shares?

    The company recently announced it has intersected high-grade gold 7.4km north of its Bellevue Gold Project in WA. This is in addition to the already estimated 2.2 Moz gold resources at an average grade of 11.3 grams per tonne. The mine is a proven, gold-rich resource that has been mined for over 100 years.

    While 11 grams in a tonne may sound small, it is very large in relation to the grade of many mining sites. It also has existing infrastructure and has reserves at lower depths than comparable gold operations in Australia. All of these factors point to a rich operation with very low operating costs.

    A combination of factors that make it likely to earn you money.

    Over the past decade, I profited from investing in Northern Star Resources Ltd (ASX: NST) as it doubled its share price again and again. I have been most impressed that Bellevue has attracted significant talent from Northern Star -people who have already taken a small gold mining company into a major gold company at a global level. 

    These include former Northern Star Mine Manager, Mr Craig Jones as the COO of Bellevue. As well as Mr Luke Gleeson as Head of Corporate Development.

    Why Gold

    Good gold mining companies regularly return good capital growth to their investors. This happens when the gold price is up, down, or flat. Right now the gold price is at historically high levels. When equities are falling or flat the shares in gold miners tend to rise. 

    Added to this is the impact of infinite quantitative easing, in particular, in the US  but also in Australia to a lesser extent. In summary, this injects large amounts of liquidity into the markets. The combination of higher amounts of cash, low-interest rates and escalating uncertainty is likely to hold gold prices high.

    Foolish takeaway

    Bellevue is one of the country’s richest gold resources at a high grade and I think it has a strong chance to make you money. A combination of factors is likely to make this a low-cost operation at a time when the gold price is high. Even if the gold price falls this deposit is still very profitable. 

    Want to discover more shares that could make you money? Read on…

    5 ASX stocks under $5

    One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.

    Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Daryl Mather owns shares of Bellevue Gold Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why I think Bellevue shares are ‘gold’ for your portfolio appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3hANeF9

  • Why I’m watching the Super Retail share price

    Pile of sporting equipment against a white background

    The Super Retail Group Ltd (ASX: SUL) share price has seen solid gains over the past 2 days after the company successfully completed its equity raising.  

    After returning from its trading halt yesterday morning, the Super Retail share price jumped around 8% higher, and today has continued its upwards trend. At the time of writing, the Super Retail share price is up by another 1.98% to $8.75 per share.

    Although the retail sector is struggling, Super Retail has managed to effectively navigate the coronavirus pandemic and could emerge stronger as consumer demand changes.

    A closer look at Super Retail

    Despite the underwhelming performance of most retailers during the coronavirus pandemic, there have been some bucking the trend. Super Retail serves as an example of a traditional retailer that has found renewed hope during Australia’s lockdown period.

    The group – which owns prominent retail outlets such as Supercheap Auto, BCF and Rebel – recently completed a $203 million equity raising to fuel its strategy and growth initiatives. The fresh capital is intended to finance the company’s omni-channel business strategy.

    Super Retail’s strategy is focused on growing its core brands and services to match changing consumer demand. Part of this includes investing in online and e-commerce programs, while also simplifying the company’s business model.  

    Despite reporting a 26.2% decline in group sales for April, Super Retail reported a strong rebound in May with group sales increasing 26.5% on the prior corresponding period. In addition, the company saw a strong shift to e-commerce, with online sales increasing 126.2% during April and May in comparison to the prior corresponding period.

    How is consumer behaviour changing?

    Super Retail is also poised to benefit from a range of changing consumer behaviours following the coronavirus lockdown. With elite and community sports returning, the group’s sporting outlets like Rebel Sport could see renewed demand. This segment already experienced a surge in demand during the lockdown period as the shutdown of gyms drove consumers to stock up on home fitness gear.

    In addition, with overseas holidays effectively cancelled in the short term, families and travellers could focus on more local activities. As a result, recreational activities like boating, camping and fishing pursuits could see renewed interest. The shift to online and digital commerce could also benefit Super Retail as the company looks to improve its click-and-collect services.  

    Should you buy Super Retail shares?

    Despite being one of the most shorted shares on the ASX, the Super Retail share price has surged more than 170% from its mid-March lows. Analysts from lead broker Morgans recently upgraded Super Retail to an ‘add’ rating. Analysts cited the group’s resilience during the coronavirus pandemic and changing consumer themes that could benefit the company. As a result, the broker slapped a $9.25 share price target for Super Retail.

    Although analysts paint an optimistic outlook for Super Retail, the company is by no means out of the woods as yet. I think a prudent strategy would be to keep Super Retail on a watchlist to see if the company’s strategy plays out.  

    Here are 5 more shares to keep an eye on.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why I’m watching the Super Retail share price appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3hDhAqs

  • Zenith Minerals share price rockets 40% after intersecting high-grade gold

    share price higher

    The Zenith Minerals Ltd (ASX: ZNC) share price was a standout performer on the market today after the company revealed strong drilling results at its Red Mountain gold project.

    Zenith Minerals shares closed 40.24% higher at 11.5 cents after rallying as much as 58.54% in early trade.

    Zenith Minerals is a micro-cap ASX miner focused on advancing its portfolio of lithium, gold and base metals projects. Including today’s gains, Zenith has a market capitalisation of around $28 million.

    Why the Zenith Minerals share price surged today

    This morning, Zenith reported results from the maiden 10-hole reverse circulation drill program completed at its wholly-owned Red Mountain project. The project is located in Queensland, within 100 kilometres of operating gold mines at Cracow and Mount Rawdon.

    The maiden drill program at Red Mountain is part of the company’s strategy to focus on its wholly-owned projects in Australia. The program was designed to test several different geological units and induced polarisation geophysical responses.

    According to today’s release, the program has returned “highly encouraging near surface high-grade gold results”, including:

    • 14 metres at 5.5 grams per tonne (g/t) gold including 6 metres at 12.3 g/t gold from surface;
    • 5 metres at 3.5 g/t gold including 2 metres at 8.0 g/t gold from 64 metres; and
    • 12 metres at 1.0 g/t gold from 42 metres including 4 metres at 2.1 g/t gold from 50 metres.

    Zenith views the initial drill program a success, with encouraging gold results returned from only a portion of a larger target area. The drilling completed to date tests around 250 metres of strike of a 1,200-metre-long, high-order gold surface anomaly.

    Following these strong results, the company noted it has a follow-up drill campaign planned for July.

    Commenting on today’s update, managing director Michael Clifford said:

    “We are delighted to announce that high-grade near surface gold mineralisation has been intersected in the maiden drill program at Red Mountain.”

    “The target generated by Zenith’s exploration team is panning out to have the hallmarks of a significant mineralised system and we are very excited about the project’s upside,” he added.

    5 ASX stocks under $5

    One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.

    Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Zenith Minerals share price rockets 40% after intersecting high-grade gold appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3dbzsp7